NCT07057765Recruiting
Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Predictive Value of CRP, Albumin, CAR, and mGPS in DLBCL: A Prospective Cohort Study on Treatment Outcomes and Toxicity
Source: ClinicalTrials.gov · Last updated 10 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 2 Jun 2025
- Start date
- 5 May 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- Ain Shams University
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07057765
What you commit to
- Study type: Observational
- Planned participants: 40
- From 5 May 2025 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of other concurrent or previous malignancies
- Uncontrolled comorbid conditions that may interfere with study participation, including:
- Diabetes mellitus
- Autoimmune diseases
- Active infections
- Chronic inflammatory diseases
- Cardiac dysfunction
- Liver cell failure
Other
- Relapsed or refractory DLBCL
- Pregnant females
Who the study is looking for
- Age ≥ 18 years and ≤ 65 years
- Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL)
- Any stage of disease (nodal or extra-nodal), with or without B symptoms
- Scheduled to receive standard systemic treatment (R-CHOP)
- ECOG performance status 0-2
- Baseline normal:
- Complete blood count (CBC)
- Hepatitis viral markers
- Liver and renal function tests
- Urine analysis
- Echocardiogram
- Additional investigations to exclude current infection if clinically indicated
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical oncology and nuclear medicine Department, Faculty of medicine, Ain Shams University Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.